Langton Julia M, Pearson Sallie-Anne
Lowy Cancer Research Centre, Adult Cancer Program, Prince of Wales Clinical School, University of New South Wales, Sydney, New South Wales, Australia.
Asia Pac J Clin Oncol. 2011 Dec;7(4):357-63. doi: 10.1111/j.1743-7563.2011.01431.x.
There have been few evaluations of the quality of computerized decision support tools in medical oncology despite their widespread use in clinical practice. In this article, we provide an in-depth quality assessment of eviQ, an Australian web-based protocol system.
We used the Appraisal of Guidelines for Research and Evaluation (AGREE-II) instrument to examine the quality of eviQ chemotherapy protocols across six domains: scope and purpose, stakeholder involvement, rigor of development, clarity of presentation, applicability, editorial independence and overall quality rating. Domain scores were categorized as high quality (scores of >70%), moderate quality (30-70%), and low quality (<30%).
eviQ was rated highly with respect to articulating its scope and purpose, clarity of presentation, applicability and on the overall rating item (scores of 72-80%). Domains addressing the involvement of stakeholders in the development process and the rigor with which protocols were developed were of moderate quality (scores of 34-37%) and the management of editorial independence and conflict of interest issues were rated in the low quality range (22%).
Our evaluation demonstrated the eviQ protocol system is generally of high quality. However, we identified a number of areas in which eviQ could improve either its development processes or the means by which these processes are communicated to end-users. This research represents the first comprehensive evaluation of oncology protocols and paves the way for continued quality assurance research to ensure that these tools meet their objective of facilitating evidence-based medicine, standardizing treatment and, ultimately, improving patient outcomes.
尽管计算机化决策支持工具在医学肿瘤学临床实践中广泛应用，但对其质量的评估却很少。在本文中，我们对澳大利亚基于网络的协议系统eviQ进行了深入的质量评估。
我们使用研究与评价指南评估（AGREE-II）工具，从六个领域检查eviQ化疗方案的质量：范围和目的、利益相关者参与、制定的严谨性、呈现的清晰度、适用性、编辑独立性和总体质量评级。领域得分分为高质量（得分>70%）、中等质量（30-70%）和低质量（<30%）。
eviQ在阐述其范围和目的、呈现的清晰度、适用性以及总体评级项目方面得分较高（得分72-80%）。涉及利益相关者在开发过程中的参与以及方案制定严谨性的领域质量中等（得分34-37%），编辑独立性和利益冲突问题的管理得分在低质量范围内（22%）。
我们 的评估表明eviQ协议系统总体质量较高。然而，我们发现eviQ在一些方面可以改进其开发过程或向最终用户传达这些过程的方式。这项研究是对肿瘤学方案的首次全面评估，为持续的质量保证研究铺平了道路，以确保这些工具实现促进循证医学、规范治疗并最终改善患者预后的目标。
